4.8 Article

Melanoma Extracellular Vesicles Generate Immunosuppressive Myeloid Cells by Upregulating PD-L1 via TLR4 Signaling

Journal

CANCER RESEARCH
Volume 79, Issue 18, Pages 4715-4728

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-19-0053

Keywords

-

Categories

Funding

  1. German Research Council [RTG2099]
  2. DKFZ-MOST Cooperation in Cancer Research [CA181]
  3. Italian Association for Cancer Research (IG grant) [18603]
  4. Italian Association for Cancer Research (Special Program Molecular Clinical Oncology 5 per mille) [12182]

Ask authors/readers for more resources

Tumor cell-derived extracellular vesicles (EV) convert normal myeloid cells into myeloid-derived suppressor cells (MDSC), inhibiting antitumor immune responses. Here, we show that EV from Ret mouse melanoma cells upregulate the expression of programmed cell death ligand 1 (PD-L1) on mouse immature myeloid cells (IMC), leading to suppression of T-cell activation. PD-L1 expression and the immunosuppressive potential of EV-generated MDSC were dependent on the expression of Toll-like receptors (TLR). IMC from Tlr4(-/-) mice failed to increase T-cell PD-L1 expression and immunosuppression with Ret-EV treatment, and this effect was dependent on heat-shock protein 86 (HSP86) as HSP86-deficient Ret cells could not stimulate PD-L1 expression on normal IMC; IMC from Tlr2(-/-) and Tlr7(-/-) mice demonstrated similar results, although to a lesser extent. HSP86-deficient Ret cells slowed tumor progression in vivo associated with decreased frequency of tumor-infiltrating PD-L1(+) CD11b(+) Gr1(+) MDSC. EV from human melanoma cells upregulated PD-L1 and immunosuppression of normal monocytes dependent on HSP86. These findings highlight a novel EV-mediated mechanism of MDSC generation from normal myeloid cells, suggesting the importance of EV targeting for tumor therapy. Significance: These findings validate the importance of TLR4 signaling in reprogramming normal myeloid cells into functional myeloid-derived suppressor cells.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Review Oncology

New targets and technologies for CAR-T cells

Fabian Freitag, Marius Maucher, Zeno Riester, Michael Hudecek

CURRENT OPINION IN ONCOLOGY (2020)

Review Oncology

Novel insights into the function ofCD24: A driving force in cancer

Peter Altevogt, Marei Sammar, Laura Hueser, Glen Kristiansen

Summary: CD24 is a highly glycosylated protein expressed primarily by immune cells and often overexpressed in human tumors. It plays a role in regulating cell migration, invasion and proliferation in cancer, associated with poor prognosis and used as a cancer stemness marker. The review summarizes recent progress on the role of CD24-Siglec-10 binding axis in tumor immunity and the potential of CD24-based immunotherapy in cancer.

INTERNATIONAL JOURNAL OF CANCER (2021)

Article Pathology

DNA Promoter Methylation and ERG Regulate the Expression of CD24 in Prostate Cancer

Yuri Tolkach, Romina Zarbl, Simone Bauer, Manuel Ritter, Joerg Ellinger, Stephan Hauser, Laura Hueser, Sabine M. Klauck, Peter Altevogt, Holger Sultmann, Dimo Dietrich, Glen Kristiansen

Summary: CD24 is overexpressed in many human cancers, including prostate cancer, and its up-regulation can be influenced by DNA methylation of the CD24 promoter. Higher levels of CD24 expression are associated with poorer outcomes in prostate cancer patients, including shorter biochemical recurrence-free survival. Overexpression of ERG and PTEN deficiency are also correlated with increased CD24 expression levels in prostate cancer.

AMERICAN JOURNAL OF PATHOLOGY (2021)

Review Cell Biology

IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy

Rebekka Weber, Christopher Groth, Samantha Lasser, Ihor Arkhypov, Vera Petrova, Peter Altevogt, Jochen Utikal, Viktor Umansky

Summary: MDSC are crucial cells generated during tumor progression that suppress the anti-tumor functions of T and NK cells. IL-6 plays a key role in regulating the accumulation and activation of MDSC, as well as stimulating tumor cell proliferation and survival. This cytokine has pleiotropic effects on immune cell populations involved in tumor development and is a potential target for tumor immunotherapy to block MDSC-mediated immunosuppression in cancer patients.

CELLULAR IMMUNOLOGY (2021)

Article Cell Biology

Potential therapeutic effect of low-dose paclitaxel in melanoma patients resistant to immune checkpoint blockade: A pilot study

Christoffer Gebhardt, Sonja C. S. Simon, Rebekka Weber, Mirko Gries, Dong Hun Mun, Raphael Reinhard, Tim Holland-Letz, Viktor Umansky, Jochen Utikal

Summary: Low-dose paclitaxel treatment may improve clinical outcomes for some advanced melanoma patients by enhancing antitumor immunity, potentially suggesting its use in combined melanoma immunotherapy.

CELLULAR IMMUNOLOGY (2021)

Article Oncology

Blocking Migration of Polymorphonuclear Myeloid-Derived Suppressor Cells Inhibits Mouse Melanoma Progression

Christopher Groth, Ludovica Arpinati, Merav E. Shaul, Nina Winkler, Klara Diester, Nicolas Gengenbacher, Rebekka Weber, Ihor Arkhypov, Samantha Lasser, Vera Petrova, Hellmut G. Augustin, Peter Altevogt, Jochen Utikal, Zvi G. Fridlender, Viktor Umansky

Summary: Myeloid-derived suppressor cells (MDSC) are a heterogeneous myeloid cell population expanded in tumor-bearing hosts and contribute to immunosuppression, making them a valuable therapeutic target. In melanoma, both polymorphonuclear (PMN) and monocytic (M) MDSC subsets have comparable immunosuppressive activities, with PMN-MDSC recruitment mediated by the CXCR2/CXCL1 axis. Inhibiting CXCR2 decreases PMN-MDSC infiltration, improves survival, and reduces metastasis, suggesting a critical role of PMN-MDSC in suppressing the NK cell-mediated anti-tumor response.

CANCERS (2021)

Article Oncology

FOXD1 promotes dedifferentiation and targeted therapy resistance in melanoma by regulating the expression of connective tissue growth factor

Qian Sun, Daniel Novak, Laura Hueser, Juliane Poelchen, Huizi Wu, Karol Granados, Aniello Federico, Ke Liu, Tamara Steinfass, Marlene Vierthaler, Viktor Umansky, Jochen Utikal

Summary: FOXD1 plays a role in regulating melanoma cell migration and invasion, with its upregulation associated with increased resistance of melanoma cells to drug treatment; through the regulation of FOXD1, CTGF can affect the sensitivity of melanoma cells to drug treatment.

INTERNATIONAL JOURNAL OF CANCER (2021)

Editorial Material Oncology

Galectin-1 Supports a Dangerous Liaison between Monocytes and Multiple Myeloma

Stefano Ugel, Vincenzo Bronte

Summary: The study reveals a novel pathway regulating the interaction between M-MDSCs and cancerous plasma cells in multiple myeloma.

CANCER IMMUNOLOGY RESEARCH (2021)

Review Oncology

Tumor promoting capacity of polymorphonuclear myeloid-derived suppressor cells and their neutralization

Christopher Groth, Rebekka Weber, Samantha Lasser, Feyza Gul Ozbay, Annina Kurzay, Vera Petrova, Peter Altevogt, Jochen Utikal, Viktor Umansky

Summary: This review summarizes the origin of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) and their relation to classical neutrophils, outlining their metastasis promoting features and promising strategies for targeting them to enhance the efficacy of cancer immunotherapy.

INTERNATIONAL JOURNAL OF CANCER (2021)

Article Cell Biology

Cardiac dysfunction in spontaneously hypertensive old rats is associated with a significant decrease of SUR2 expression

Ruslan B. Strutynskyi, Serhii Goncharov, Lesya Tumanovska, Vasyl S. Nagibin, Victor E. Dosenko

Summary: The study revealed the association between changes in K-ATP channel subunits and alterations in heart function and structure in spontaneously hypertensive rats, suggesting that the significant decrease in SUR2 expression may be one of the mechanisms of heart failure decompensation.

MOLECULAR AND CELLULAR BIOCHEMISTRY (2021)

Article Oncology

Tumor-Derived Factors Differentially Affect the Recruitment and Plasticity of Neutrophils

Ludovica Arpinati, Naomi Kaisar-Iluz, Merav E. Shaul, Christopher Groth, Viktor Umansky, Zvi G. Fridlender

Summary: Neutrophils, an abundant type of circulating leukocytes, play crucial roles in cancer biology. This study reveals that tumor-associated neutrophils can originate from different subpopulations and exhibit plasticity under the influence of chemokines and tumor-derived factors, potentially transitioning through phenotypical changes.

CANCERS (2021)

Article Multidisciplinary Sciences

Stromal changes in the aged lung induce an emergence from melanoma dormancy

Mitchell E. Fane, Yash Chhabra, Gretchen M. Alicea, Devon A. Maranto, Stephen M. Douglass, Marie R. Webster, Vito W. Rebecca, Gloria E. Marino, Filipe Almeida, Brett L. Ecker, Daniel J. Zabransky, Laura Huser, Thomas Beer, Hsin-Yao Tang, Andrew Kossenkov, Meenhard Herlyn, David W. Speicher, Wei Xu, Xiaowei Xu, Elizabeth M. Jaffee, Julio A. Aguirre-Ghiso, Ashani T. Weeraratna

Summary: The aged lung microenvironment provides a permissive niche for the growth and dissemination of melanoma cells, while age-related changes in the skin suppress melanoma growth but drive dissemination. Reprogramming of lung fibroblasts and activation of WNT5A promote the metastasis and dissemination of melanoma cells by inhibiting WNT5A in melanoma cells.

NATURE (2022)

Article Oncology

STAT3 inhibitor Napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing mice

Rebekka Bitsch, Annina Kurzay, Feyza Oezbay Kurt, Carolina De la Torre, Samantha Lasser, Alisa Lepper, Alina Siebenmorgen, Verena Mueller, Peter Altevogt, Jochen Utikal, Viktor Umansky

Summary: STAT3 inhibitor Napabucasin can block the accumulation and activity of MDSC and improve the prognosis of patients with malignant melanoma. Patients with high expression of activated STAT3 in M-MDSC have shorter progression-free survival, indicating that STAT3 may be a promising therapeutic target in the treatment of malignant melanoma.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

No Data Available